Literature DB >> 1722460

Concentration of azithromycin in human prostatic tissue.

G Foulds1, P Madsen, C Cox, R Shepard, R Johnson.   

Abstract

Prostatic tissue was obtained from 36 patients at two study locations and assayed for azithromycin by HPLC or bioassay. The mean concentration of azithromycin in human prostatic tissue (2.54 micrograms/ml) 14 h after 500 mg oral dosing (two 250 mg doses 12 h apart) was much greater than plasma concentrations (less than or equal to 0.1 micrograms/ml). Azithromycin was slowly eliminated from prostatic tissue (half-life 60 h) and a mean concentration of 0.62 micrograms/ml remained 137 h after dosing.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1722460     DOI： 10.1007/bf01975845

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


  13 in total

1.  High-performance liquid chromatographic assay with electrochemical detection for azithromycin in serum and tissues.

Authors:  R M Shepard; G S Duthu; R A Ferraina; M A Mullins
Journal:  J Chromatogr       Date:  1991-04-19

2.  Concentrations of azithromycin in human tonsillar tissue.

Authors:  G Foulds; K H Chan; J T Johnson; R M Shepard; R B Johnson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

3.  Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms.

Authors:  J Retsema; A Girard; W Schelkly; M Manousos; M Anderson; G Bright; R Borovoy; L Brennan; R Mason
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

4.  Correlation of the extravascular pharmacokinetics of azithromycin with in-vivo efficacy in models of localized infection.

Authors:  A E Girard; D Girard; J A Retsema
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

5.  In-vitro activity of azithromycin, erythromycin, ciprofloxacin and norfloxacin against Neisseria gonorrhoeae, Haemophilus ducreyi, and Chlamydia trachomatis.

Authors:  L Slaney; H Chubb; A Ronald; R Brunham
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

6.  Relationship of high tissue concentrations of azithromycin to bactericidal activity and efficacy in vivo.

Authors:  J A Retsema; A E Girard; D Girard; W B Milisen
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

7.  The pharmacokinetics of azithromycin in human serum and tissues.

Authors:  G Foulds; R M Shepard; R B Johnson
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

8.  Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-AZA-9a-homoerythromycin A derivatives; a new class of macrolide antibiotics, the azalides.

Authors:  G M Bright; A A Nagel; J Bordner; K A Desai; J N Dibrino; J Nowakowska; L Vincent; R M Watrous; F C Sciavolino; A R English
Journal:  J Antibiot (Tokyo)       Date:  1988-08       Impact factor: 2.649

9.  The in-vitro activity of CP-62,993 against Haemophilus influenzae, Branhamella catarrhalis, staphylococci and streptococci.

Authors:  K T Dunkin; S Jones; A J Howard
Journal:  J Antimicrob Chemother       Date:  1988-04       Impact factor: 5.790

10.  Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution.

Authors:  A E Girard; D Girard; A R English; T D Gootz; C R Cimochowski; J A Faiella; S L Haskell; J A Retsema
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191
View more
  8 in total

1.  Concentrations of azithromycin in human tonsillar tissue.

Authors:  G Foulds; K H Chan; J T Johnson; R M Shepard; R B Johnson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

2.  Fluoroquinolone-macrolide combination therapy for chronic bacterial prostatitis: retrospective analysis of pathogen eradication rates, inflammatory findings and sexual dysfunction.

Authors:  Vittorio Magri; Emanuele Montanari; Višnja Škerk; Alemka Markotić; Emanuela Marras; Antonella Restelli; Kurt G Naber; Gianpaolo Perletti
Journal:  Asian J Androl       Date:  2011-07-18       Impact factor: 3.285

3.  Pharmacokinetics of azithromycin administered alone and with atovaquone in human immunodeficiency virus-infected children. The ACTG 254 Team.

Authors:  L Y Ngo; R Yogev; W M Dankner; W T Hughes; S Burchett; J Xu; B Sadler; J D Unadkat
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

4.  Effects of azithromycin in combination with vancomycin, daptomycin, fosfomycin, tigecycline, and ceftriaxone on Staphylococcus epidermidis biofilms.

Authors:  Elisabeth Presterl; Stefan Hajdu; Andrea M Lassnigg; Alexander M Hirschl; Johannes Holinka; Wolfgang Graninger
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

Review 5.  Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D H Peters; H A Friedel; D McTavish
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

Review 6.  Azithromycin clinical pharmacokinetics.

Authors:  N J Lalak; D L Morris
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

7.  Azithromycin Concentrations and Microbiology of Tonsils during Weekly Medication in Patients with Recurrent Tonsillitis.

Authors:  A Schmedes; T Lildholdt; P Schouenborg; D W Eriksen
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

8.  Pharmacokinetics of a single 1g dose of azithromycin in rectal tissue in men.

Authors:  Fabian Y S Kong; Thusitha W Rupasinghe; Julie A Simpson; Lenka A Vodstrcil; Christopher K Fairley; Malcolm J McConville; Jane S Hocking
Journal:  PLoS One       Date:  2017-03-28       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.